Expertise in
4
conditions

Dr. Vikki A. Canfield

Hematology Oncology
4205 Mcauley Blvd, 375, 
Oklahoma City, OK 
Expertise in
4
conditions
4205 Mcauley Blvd, 375, 
Oklahoma City, OK 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Vikki Canfield is a Hematologist Oncology provider in Oklahoma City, Oklahoma. Dr. Canfield is highly rated in 4 conditions, according to our data. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Angiosarcoma, and Inflammatory Breast Cancer.

Her clinical research consists of participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Licenses
Internal Medicine in OK
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

4205 Mcauley Blvd, 375, Oklahoma City, OK 73120

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
Enrollment Status: Terminated
Publish Date: July 30, 2021
Intervention Type: Drug
Study Drugs: Tesetaxel and Capecitabine, Capecitabine
Study Phase: Phase 3
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)
Enrollment Status: Completed
Publish Date: March 08, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 2 Less Clinical Trials
Similar Doctors
Expertise in
87
conditions
Dr. Michael J. Keefer
Hematology Oncology | Oncology
Expertise in
87
conditions
Dr. Michael J. Keefer
Hematology Oncology | Oncology

Mercy Clinic Oklahoma Communities

4300 Mcauley Blvd, 
Oklahoma City, OK 
 (0.2 miles away)
405-936-5455
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Keefer is a Hematologist Oncology specialist and an Oncologist in Oklahoma City, Oklahoma. Dr. Keefer is highly rated in 87 conditions, according to our data. His top areas of expertise are Chondrosarcoma, Osteosarcoma, Paget Disease of the Breast, Breast Cancer, and Bone Marrow Aspiration. Dr. Keefer is currently accepting new patients.

Expertise in
45
conditions
Dr. Abby R. Bova
Hematology Oncology | Hematology | Oncology
Expertise in
45
conditions
Dr. Abby R. Bova
Hematology Oncology | Hematology | Oncology

Mercy Clinic Oklahoma Communities

4300 Mcauley Blvd, 
Oklahoma City, OK 
 (0.2 miles away)
405-936-5455
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Abby Bova is a Hematologist Oncology specialist and a Hematologist in Oklahoma City, Oklahoma. Dr. Bova is highly rated in 45 conditions, according to our data. Her top areas of expertise are Paget Disease of the Breast, Breast Cancer, Angiosarcoma, Inflammatory Breast Cancer, and Bone Marrow Aspiration. Dr. Bova is currently accepting new patients.

Expertise in
25
conditions
Dr. Mohammad A. Razaq
Hematology Oncology | Emergency Medicine | Oncology
Expertise in
25
conditions
Dr. Mohammad A. Razaq
Hematology Oncology | Emergency Medicine | Oncology

Mercy Clinic Oklahoma Communities

4300 Mcauley Blvd, 
Oklahoma City, OK 
 (0.2 miles away)
405-936-5455
Languages Spoken:
English, Hindi, Punjabi, Urdu
See accepted insurances
Accepting New Patients

Mohammad Razaq is a Hematologist Oncology specialist and an Emergency Medicine provider in Oklahoma City, Oklahoma. Dr. Razaq is highly rated in 25 conditions, according to our data. His top areas of expertise are Lung Cancer, Small Cell Lung Cancer (SCLC), Pleuropulmonary Blastoma, Non-Small Cell Lung Cancer (NSCLC), and Bone Marrow Aspiration. Dr. Razaq is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Canfield's expertise for a condition
ConditionClose
    View All 62 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile